Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms. MDS is a group of heterogeneous clonal ...
New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.
Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ...
The FDA approved vorasidenib (Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The drug -- an IDH1 and IDH2 inhibitor - ...
Scientists have discovered a new mechanism by which cancerous cells in acute myeloid leukemia (AML) regulate the protein IDH2 (isocitrate dehydrogenase2) known to be mutated in cancer, to increase the ...
Genetic variations in semaphorin/neuropilin signaling to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab-based chemotherapy.
Researchers revealed new insights into how acute myeloid leukemia (AML) develops and progresses, according to a new study. Researchers revealed new insights into how acute myeloid leukemia (AML) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback